Meet the MBA Class of ’27: Haley Lassiter
Haley Lassiter
A bioengineer turned commercialization strategist, Haley bridges science and business to deliver measurable results. At Pathways Preclinical Partners, she develops branding, go-to-market, and investor strategies that accelerate biotech client acquisition and partnerships. Previously at Obatala Sciences, she co-led commercialization of ObaGel® ECM, built technical collateral, and drove a website/CRM rebuild that secured six-figure pharma contracts. A Harvard visiting fellow in bioengineering, she advanced obesity-on-a-chip models to support FDA regulatory requirements and therapeutic evaluation. With expertise spanning R&D, marketing, and strategy, Haley helps biopharma clients align complex science with growth, partnerships, and operational excellence.
Interested in advancing your education and/or career? Learn more about Freeman’s MBA programs. Find the right program for you.
Recommended Reading
- A Guide to Campus Life for Grad Students
- MBA vs. Master of Management in Energy: Key Differences
- How Long Is an MBA Program?
- MBA Accreditation Types and Benefits
- Executive MBA vs. MBA: What Are the Differences?
- What Is the ROI of an MBA?
- Is an MBA Worth It?
- MBA vs. Master’s in Finance: Key Differences
Other Related Articles
- Alternative Investments Conference offers students a different path to success
- For EMBA student, program is all about the journey
- Community leaves lasting mark on Tulane Athletics Hall of Famer
- LinkedIn ranks Freeman among Top 100 Global MBA Programs
- Freeman jumps 11 spots in Bloomberg Businessweek MBA ranking
- Freeman welcomes new energy students with inaugural Hard Hat Ceremony
- MBAs study the global business of sustainability in Madrid
- Students help non-profit restaurant grow catering business